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Abstract 
 
Patients with autoimmune polyendocrine syndrome type 1 (APS-1) suffer from multiple 
organ-specific autoimmunity with autoantibodies against target tissue-specific autoantigens. 
Endocrine and also non-endocrine organs such as skin, hair follicles and liver are targeted by the 
immune system. Despite sporadic observations of pulmonary symptoms among APS-1 patients, an 
autoimmune mechanism for pulmonary involvement has not been elucidated. We report here on a 
subset of APS-1 patients with respiratory symptoms. Eight patients with pulmonary involvement 
were identified. Severe airway obstruction was found in four patients leading to death in two. 
Immunoscreening of a cDNA library using serum samples from a patient with APS-1 and 
obstructive respiratory symptoms identified a putative potassium channel regulator (KCNRG) as a 
pulmonary autoantigen. Reactivity to recombinant KCNRG was assessed in 110 APS-1 patients 
using immunoprecipitation. Autoantibodies to KCNRG were present in seven of the eight patients 
with respiratory symptoms, but in only one of nine APS-1 patients without respiratory symptoms. 
Expression of KCNRG messenger RNA and protein was found to be predominantly restricted to the 
epithelial cells of terminal bronchioles. Autoantibodies to KCNRG, a protein mainly expressed in 
bronchial epithelium, are strongly associated with pulmonary involvement in APS-1. This finding 
will facilitate the characterisation and diagnosis of the pulmonary manifestations of APS-1. 
  
 
 
 
Introduction 
Autoimmune Polyendocrine Syndrome Type 1 (APS-1), also known as Autoimmune 
Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED, OMIM 240300), is a rare 
disorder caused by mutations in the Autoimmune Regulator (AIRE) gene1. Patients with APS-1 
progressively develop multiple organ-specific autoimmunity of endocrine and non-endocrine 
tissues. Loss of function of the Aire protein results in decreased expression of self-antigens in 
medullary thymic epithelial cells and in failure to establish central tolerance to a range of different 
autoantigens2. Multiple autoantibodies directed against specific intracellular autoantigens are found. 
Well defined autoantigens in APS-1 include 21-hydroxylase in the adrenal cortex, tryptophan 
hydroxylase in intestinal serotonin-producing cells and NACHT, leucine rich repeat and PYD 
containing 5 (NALP5) in parathyroid glands3-5. Detection of autoantibodies can help in the 
diagnosis of a disease component or predict its future development5,6. Hypoparathyroidism and 
Addison’s disease are the most frequent disease components, and more than 20 different 
autoimmune manifestations have been identified in APS-11,6,7. Major histocompatibility complex 
(MHC) and non MHC allelic variation are believed to influence disease expression 8,9. 
Identification of tissue-specific autoantigens in APS-1 provides useful diagnostic markers and 
increases our understanding of the variable expression of disease in individuals6.  
 
Although pulmonary disease has been sporadically observed in APS-1 patients, an 
immune-mediated mechanism has not been established10,11. We describe APS-1 patients with 
autoimmune pulmonary disease, and a potassium channel regulating protein preferentially 
expressed in the epithelial cells of terminal bronchioles (KCNRG) as the putative target antigen.  
 
 
Results  
Identification of Airway Inflammation as a Component of APS-1 
Severe respiratory symptoms were seen in four of 110 APS-1 patients described below (patients 
1—4, Table 1) Five additional cases with respiratory involvement and/or KCNRG autoantibodies 
were subsequently identified after recruitment to the study (patients 5-9, Table 1). 
 
Patient 1 developed asthma-like respiratory symptoms aged 5 years. At age 10 the symptoms 
worsened, and were poorly controlled by inhaled and oral glucocorticoids. By 11, APS-1 was 
diagnosed. Lung function tests showed obstruction with reduced forced vital capacity (FVC), forced 
expiratory volume (FEV1) and forced expiratory flow (FEF 25-75%) at 73%, 48% and 26% of 
predicted. Skin prick tests were negative for all allergens tested. Chest CT scan showed 
bronchiectasis with peribronchial ground-glass opacities (Figure 1A).  Treatment with prednisolone 
(2 mg/kg/d) markedly improved the respiratory symptoms, but relapses were severe on dose 
reduction. Lung biopsy showed inflammation with peribronchiolar lymphoid infiltrate in the small 
bronchioles (Figure 1C and D). Azathioprine was started at 14 years of age with little 
steroid-sparing effect. Mycophenolate mofetil (750 mg twice daily) was commenced at age 15.5 
years, with good effect and prednisolone was decreased to 0.14 mg/kg/d. Respiratory symptoms and 
CT scan appearances improved and improvement was maintained at evaluation 2.5 years later 
(Figure 1B). 
 
Patient 2 was diagnosed with APS-1 in early childhood, but died at the age of 18 of cor pulmonale 
and respiratory failure. Autopsy was not performed. From the age of 5 he had lower respiratory 
tract infections at least 2-3 times a year. Chest X-ray and CT scan revealed bilateral bronchiectasis 
from the age of 10 years.  Lung function tests showed reduced FEV1 (< 40%) and FVC at 50-60% 
of predicted. His respiratory symptoms deteriorated with exercise intolerance, shortness of breath 
and growth failure.  Exacerbations were poorly controlled by cycles of antibiotic and glucocorticoid 
therapy. Chronic colonization with Burkholderia cepacia developed. By age 14 years he was 
 
 
 
oxygen dependent with FEV1 and FVC at 14% and 13%, respectively of expected. Other causes 
were excluded by extensive investigations including sweat test, nasal mucosal brush biopsy and 
genetic analysis for cystic fibrosis. 
 
Patient 3, currently 19 years old, was diagnosed with hepatitis due to APS-1 aged 9 months. 
Dyspnoea in early childhood was initially diagnosed as asthma. By age 10 years, bronchiolitis 
obliterans organizing pneumonia had developed, with bronchiectasis on the CT scan verified by 
lung biopsy (Figure 1E and F). He suffered recurrent lower respiratory tract infections. He is 
currently oxygen-dependent with an FVC and FEV1 at 31% and 18%, respectively of predicted.  
 
Patient 4 presented with chronic cough in childhood.  APS-1 was diagnosed at 9 years of age. By 
20, he had established bronchiectasis on chest X-ray and CT scan. Spirometry showed airway 
obstruction. The patient had frequent episodes of “infectious bronchitis” and gradually deteriorated. 
At age 34 years, he was admitted to intensive care because of hypoxemic pneumonia. Lung biopsy 
showed a severe peribronchiolar infiltrate (Figure 1G and H). He died of chronic respiratory 
failure at the age of 37.  
 
Immunoscreening of a cDNA Library and Autoantibody Assay on KCNRG 
By immunoscreening a bovine cDNA library with serum from patient 6 with obstructive pulmonary 
disease and hypoparathyroidism, we found three independent clones encoding KCNRG (GenBank 
accession number AY190923). KCNRG-specific autoantibodies were subsequently sought in sera 
from 105 APS-1 unselected patients independent of the presence of respiratory symptoms. Four of 
these 105 sera (patients 6 to 9 in Table 1 - including patient 6 used for immunoscreening) were 
positive. None of 252 control sera were positive (Figure 2A). These findings led us to test for 
immunoreactivity to KCNRG in sera from APS-1 patients selected for the presence of severe 
pulmonary disease (patient 15, Table1). Four of these five patients (patient 14, Table 1) had high 
titer antibody. In total 8 of 110 (7.2 %) APS-1 patients investigated, displayed the KCNRG 
autoantibodies. 
 
Expression Analysis of KCNRG Messenger RNA and Protein 
Microarray expression databases such as GNF SymAtalas and GeneNote, state that tissue 
expression of KCNRG is almost ubiquitous 17,18. Nevertheless, we investigated the tissue expression 
of KCNRG by Northern blotting and quantitative real-time PCR. Northern blot (Supplementary 
Figure 1) demonstrated that expression of KCNRG was actually restricted to the lungs. Quantitative 
PCR analysis (Figure 2B) showed that, mRNA expression of KCNRG was predominantly 
restricted to the lungs. However, it also revealed that KCNRG mRNA was expressed to a low 
extent in the pancreas and prostate. Nevertheless, expression in other tissues was at much lower 
levels than in lungs. Immunohistochemistry on bovine lung using a rabbit polyclonal antiserum 
developed against KCNRG, specifically stained epithelial cells of the terminal bronchioles 
(Figure 3B). To further exclude the ubiquitous expression of the KCNRG at protein level, we used 
the antiserum directed against KCNRG and stained a human multi-tissue array. The results were in 
line with the results for mRNA expression experiments (Supplementary Figure 6).  
 
Immunostaining of Lung Tissue with APS-1 Sera 
Immunofluorescence of bovine lung with anti-KCNRG positive sera from APS-1 patients, showed 
specific staining of the epithelial cells of terminal bronchioles with two of the three sera used 
(Figure 3 E-F). The staining pattern of patient sera was identical to that of the KCNRG-antiserum. 
No staining was seen with control sera from anti-KCNRG negative APS-1 patients (Figure 3 H-I) 
or healthy blood donors (Figure 3 J-K). 
 
The specificity of APS-1 patient autoantibodies for KCNRG, was confirmed by preabsorption 
studies. In these experiments, preabsorption of the patient serum samples with recombinant 
  
 
 
KCNRG abolished the staining of the terminal bronchioles (Supplementary Figure 5 B and E). In 
contrast, preabsorption of the sera with equal amount of Luciferase did not reduce specific staining 
of the terminal bronchioles (Supplementary Figure 5C and F).  
 
Discussion 
We present evidence showing that pulmonary autoimmunity is a component of APS-1 and have 
identified the KCNRG protein as a target autoantigen. Strong serum reactivity against KCNRG was 
found in most APS-1 patients (7 of 8) with respiratory involvement of varying severity - with fatal 
outcomes in some cases. We demonstrate that KCNRG expression is mainly restricted to the 
epithelial cells of terminal bronchioles. These findings have significance for clinicians who care for 
patients with APS-1 and provide a tool to define and investigate the possible pulmonary 
autoimmunity in APS-1 and thereby distinguish it from concurrent obstructive lung disease or 
lower respiratory tract infections. The terminal bronchiole is a previously unrecognized 
autoimmune target in APS-1. 
 
Symptoms displayed were quite variable (Table 1). Patients 6-8 had relatively mild symptoms, well 
controlled by inhaled beta2-agonists, inhaled glucocorticoid and mucolytic drugs, and may go 
unnoticed in the context of APS-1 where several disabling disease components can mask less 
obvious symptoms. In contrast, four patients (patients 1-4, Table 1) had severe respiratory 
symptoms, initially asthma-like but evolving into severe obstructive lung disease with radiological 
signs of bronchiectasis. Two died from pulmonary disease at the age of 18 and 37 years, another 
patient is oxygen-dependent at the age of 18, but patient 1 displayed dramatic improvement when 
treated with mycophenolate mofetil immunosuppression. In patients 1, 2 and 4, the relationship 
between the respiratory symptoms and APS-1 was not considered initially even when cystic fibrosis 
had been ruled out. All of these four patients had high titer autoantibodies to KCNRG and early 
knowledge of this may have influenced their management. KCNRG autoantibodies are however, 
discordant with pulmonary manifestations in two APS-1 patients (Patients 5 and 9). Patient 5 was 
negative for KCNRG autoantibodies when her initial respiratory symptoms appeared. A presumed 
lymphocytic interstitial pneumonia (LIP) had remitted after hydroxychloroquine treatment. 
However, in addition to APS-1, this patient had recurrent pulmonary bacterial infections due to 
antibody deficiency. She responded well to intravenous immunoglobulin replacement therapy 
(IVIG), but has had recurrent unexplained respiratory symptoms thought to be due to LIP. This 
treatment may have altered this patient’s pulmonary presentation and/or masked the detection of 
autoantibodies. To our knowledge, this patient is the only case of APS-1 on IVIG therapy. Patient 9 
was positive for KCNRG autoantibodies but has no respiratory symptoms or pathological signs on 
chest X-ray,spirometry, or plethysmography . In addition, it should be taken into consideration that 
respiratory disease in this report was defined from patients’ self-reported symptoms and not by 
prospective lung function tests. I may therefore be possible that some additional cases of patients 
with undetected respiratory disease may exist in our cohort. These possible cases apparently do not 
show autoantibody response to KCNRG. 
 
The absence of a perfect correlation between presence of KCRNG autoantibodies and respiratory 
manifestation is not surprising. It parallels other autoantibody responses in APS-1 and other 
autoimmune conditions where only a fraction of autoantibody-positive individuals manifest the 
clinical disease component at any time point19,20. There may also be heterogeneity of the immune 
response in APS-1 and other pulmonary autoantigens could be targeted. Since we could only test a 
single serum from each patient, it is impossible to rule out fluctuation of KCNRG autoantibodies 
over time. Alternatively, APS-1 patients may present with confounding respiratory symptoms due 
to common intercurrent diseases (asthma and infections) or candida infections.  
 
 
 
 
Although pulmonary autoimmunity hitherto has not been considered as a component of APS-1 in 
humans11,21, the animal model for APS-1, Aire deficient mice display pulmonary pathology of 
variable severity depending on the background strain. Aire deficient mice on C57BL6 and Balb/c 
background display modest pulmonary disease while Aire deficient mice on NOD and SJL 
background strain have severe and fatal lung pathology comparable to the histological appearances 
in our APS-1 patients9. Phenotypic variability may therefore depend on genetic background in 
humans. 
 
Is KCNRG is a valid candidate bronchial autoantigen? Northern blotting and quantitative real-time 
PCR analysis demonstrate predominant expression in lungs and immunohistochemistry localize the 
KCNRG protein to epithelial cells of small bronchioles. Two human splice variants of KCNRG 
encoding 31 and 26 kDa isoforms have been characterized by ourselves and others22. KCNRG has a 
homology to the cytoplasmic tetramerization domain of voltage gated potassium channels and 
KCNRG inhibits potassium fluxes in vitro suggesting that KCNRG may function as a potassium 
channel regulating protein22. We have experimentally confirmed the tendency of KCNRG to form 
tetramers in vitro (Supplementary Figure 2). Although the exact role of KCNRG in the lung 
remains to be determined, a role of potassium channels in histamine-induced bronchoconstriction 
and plasma exudation has been postulated and drugs interfering with potassium channels have been 
proposed to treat bronchoconstriction23,24. It is also well recognized that autoantibodies to calcium 
and potassium channels can cause autoimmune disease such as the Lambert-Eaton Myasthenic 
Syndrome 25. 
 
We have identified KCNRG, a putative potassium channel regulating protein expressed in bronchial 
epithelial cells, as an autoantigen in APS-1 associated with pulmonary manifestations. We report 
pulmonary autoimmunity as a disease component in APS-1 with a potentially fatal outcome. Early 
recognition of pulmonary autoimmunity and its distinction from asthma and recurrent bacterial 
infections is important, since the autoimmune bronchiolitis in APS-1 may respond well to 
immunosuppression. Our findings also highlight APS-1 as a condition, which provides an important 
opportunity to study autoimmunity in the lungs. 
 
Materials and Methods  
Ethics Approval 
Informed written consent was obtained for all participants. Ethics committee approval was obtained 
from the Uppsala University (Permit UPS-02-415).  
 
Patients and Sera 
Serum samples were analyzed from 110 APS-1 patients (10 Swedish, 19 Norwegian, 59 Finnish, 18 
Italian, 4 French and 1 from UK) with at least two of the major clinical components of APS-1 
(Addison’s disease, hypoparathyroidism, and chronic mucocutaneous candidiasis). The following 
diagnostic criteria were used: mucocutanous candidiasis: candidal infections in the oral mucosa, 
skin or nails for more than 3 months. Hypoparathyroidism: Subnormal plasma calcium 
concentration (<2.15 mmol/L) and supranormal plasma phosphate concentration together with 
normal or low PTH concentrations, and normal renal function. Addison’s disease: subnormal serum 
cortisol together with elevated plasma ACTH concentrations, or failure to reach s-cortisol of 
550 nmol/L at 30 or 60 min of an ACTH stimulation test. The majority of the patients diagnosed 
with Addison’s disease also displayed specific 21-hydroxylase autoantibodies. The majority of the 
patients were also demonstrated to have typical mutations in the Aire gene (102 of the 
110 patients). All of the 9 patients with KCNRG autoantibodies had typical mutations in the Aire 
gene. Detection of respiratory symptoms: Due to the high number of included patients from several 
centers in six different countries, we could not systematically perform lung function examination on 
the entire cohort. Hence, respiratory symptoms described here were defined from patient self-report 
  
 
 
of dyspnoea or cough, leading to relevant pulmonary work-up to exclude other causes of respiratory 
symptoms. Detailed information on each of the patient’s respiratory symptoms is included in the 
Results section of the manuscript. Control sera were obtained from patients with: allergic asthma 
(n=24), non-allergic asthma (n=24), chronic obstructive pulmonary disease (COPD) (n=45), 
Sjögren’s syndrome with respiratory symptoms (n=8), Addison’s disease (n=30), type 1 diabetics 
(n=30), and healthy blood donors (n=91). 
 
Construction and Screening of cDNA Expression Library  
Messenger RNA was isolated from bovine tissue, obtained at a local abattoir. A cDNA expression 
library was constructed in the λ-ZAP Express vector (Stratagene, La Jolla, CA). The library was 
immunoscreened with serum from an APS-1 patient (Patient 6, Table 1) as previously described12. 
Isolated clones were sequenced and their DNA and deduced amino acid sequences were analyzed 
using the Basic Local Alignment Sequence Tool (BLAST)13. 
Generation of 35S Labeled Human KCNRG and Immunoprecipitation/ Radioimmunoassay 
for KCNRG Autoantibodies 
The KCNRG-encoding clone, isolated by immunoscreening of the cDNA library, was used as 
template for coupled in vitro transcription, translation and labeling with 35S-Methionine using the 
TnT system (Promega, Madison, WI)14. Autoantibody reactivity against the clones was determined 
by immunoprecipitation followed by analysis of the immunoprecipitates on SDSPAGE, and/or 
evaluation of the precipitated radioactivity on an automated beta counter as previously 
described15,16. 
 
Expression Analysis by Quantitative PCR and Northern Blot  
Complementary DNA from normal human tissues obtained from BD Biosciences (Palo Alto, CA, 
USA) were normalized and used as templates for quantitative PCR analysis on an iCycler MyiQ 
(Bio-Rad, Hercules, CA). Primer sequences, PCR conditions and Conditions for the Northern 
blotting is provided in the Supplementary appendix.  
KCNRG Antiserum Generation and Immunoblotting 
An antiserum against KCNRG was raised by immunization of rabbits with the peptide 
LPPQRPSYHDLVFQC, present in both human and bovine KCNRG and affinity-purified on a 
peptide column. Specificity was confirmed by immunoblotting with bovine lung total protein 
extract and by absorption studies in which the reactivity was blocked by preincubation with the 
peptide used for immunization. 
 
Immunohistochemistry 
Samples of bovine lung were fixed and paraffin embedded. Sections of 4 μm thickness were 
deparaffinized, microwave treated, blocked and incubated overnight at 4°C with the KCNRG 
antiserum (dilution 1:1000). The slides were then washed, exposed for 30 minutes to a biotinylated 
secondary antibody and developed using the VECTASTAIN ABC system (Vector Laboratories, 
Burlingame, CA) and ChemMate DAKO Envision Detection kit (DAKO, Glostrup, Denmark). 
Negative control slides were used for comparison. 
 
Immunofluorescence and Laser-Scanning Confocal Microscopic Analysis  
Cryosections (6 μm) of bovine lung tissue were air dried, blocked and incubated with APS-1 
patient’s sera with KCNRG reactivity (dilution 1:400). The slides were incubated with FITC 
conjugated secondary antibodies (dilution 1:200) for 30 min. Slides were analysed on a Zeiss LSM 
510 confocal microscope. Sera from healthy blood donors and from APS-1 patients without 
KCNRG-specific autoantibodies were used as negative controls.  
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Table 1. Description of the APS-1 patients with respiratory symptoms or KCNRG antibodies 
Patient # 
(country of 
origin) 
Age of onset of 
pulmonary 
manifestations 
Initial 
pulmonary 
symptoms 
Pulmonary 
function tests/ X-
rays/ pulmonary 
histology 
Management Outcome Antibodies to 
KCNRG 
APS-1 manifestations Aire gene 
mutation 
1 (France) 
 
Childhood 
(≈5 years of age) 
Obstructive symptoms 
with frequent 
exacerbations  
Obstructive pulmonary 
disease/ ground glass 
opacities, bronchiectasis/ 
12 yr: bronchiolopathy and 
peribronchiolar 
inflammatory infiltrate  
Steroids, azathioprine, 
mycophenolate mofetil 
Steroid dependence: 
marked improvement 
on mycophenolate 
mofetil 
+ 
Candidiasis, hypoparathyriodism, 
Addison’s  disease, alopecia, 
pernicious anemia, exocrine 
pancreas insufficiency 
62C>T/  
1096-1G>A 
2 (Italy) Childhood 
Several lower 
respiratory tract 
infections from 5 years 
of age 
Obstructive pulmonary 
disease/ 10 yr: bilateral 
bronchiectasis  
Antibiotics, supportive 
care 
Death at 18 yr due to 
cor pulmonare and 
terminal respiratory 
failure. 
+ 
Candidiasis, hypoparathyroidism, 
Addison’s  disease, pernicious 
anemia, intestinal 
dysfunction/malabsorbtion 
607C>T/ 769C>T 
3 (Finland) Childhood Asthma-like symptoms 
Obstructive and restrictive 
pulmonary disease/ 
bronchiectasis/ 10 yr: 
bronchiolopathy, 
bronchiolitis obliterans 
Steroids Severe respiratory failure + 
Candidiasis, hepatitis, intestinal 
dysfunction/ malabsorption, 
Addison’s disease 
769C>T/ 769C>T 
4 (France) Childhood Chronic cough 
Obstructive then restrictive 
pulmonary disease/ 20 yr: 
bronchiectasis/ 34 yr: 
peribronchiolar 
inflammatory infiltrate 
Antibiotics, supportive 
care 
Exacerbations with 
recurrent pulmonary 
infections; death at 
37 yr of chronic 
respiratory failure 
+ Candidiasis, hypoparathyroidism, Addison’s disease, hepatitis 
964del13/ 
964del13 
5 (United 
Kingdom) Childhood (11 yr) 
Cough, dyspnea, 
thoracic pain 
Restrictive pulmonary 
disease with decreased 
DL,CO/ bilateral interstitial 
infiltrate and peribronchial 
ground-glass opacity / 
lymphocytic bronchiolitis 
Hydroxychloroquine 
from 11 to 18 yr 
Improvement at the 
age of 20 yr - 
Candidiasis, hypoparathyroidism, 
Addison’s disease, hepatitis, 
ectodermal dysplasia, specific 
antibody deficiency (failure to 
respond to polysaccharide vaccine 
and recurrent bacterial infections), 
on intra-venous immunoglobulin 
964del13/ 
964del13 
6 (Sweden) Young adulthood 
Airway 
hyperresponsiveness 
and obstructive 
symptoms  
N.D. 
Inhaled terbutaline and 
budesonide, 
acetylcysteine 
Mild to moderate 
symptoms of 
bronchial 
hyperresponsiveness. 
+ 
Candidiasis, hypoparathyroidism, 
Addison’s disease, 
hypogonadism, alopecia, vitiligo 
769C>T/ 769C>T 
7 (Sweden) 
 Young adulthood 
Airway 
hyperresponsiveness. N.D. 
Inhaled terbutaline, 
acetylcysteine Improvement + 
Candidiasis, hypoparathyroidism, 
Addison’s disease, hypogonadism, 
hepatitis, intestinal 
dysfunction/malabsorbtion 
769C>T/ 769C>T 
8 (Sweden) 
 Young adulthood 
Airway 
hyperresponsiveness. 
Respiratory symptoms. 
Infection induced 
exacerbations. 
N.D. Inhaled terbutaline, acetylcysteine 
Improvement; 
occasionally, mild 
respiratory symptoms 
+ 
Candidiasis, hypoparathyroidism, 
Addison’s disease, hypogonadism, 
intestinal 
dysfunction/malabsorbtion, 
hepatitis, gastritis 
M388fsX36 
/ C62>T 
9 (Norway) N.A. No respiratory symptoms N.D. N.A. 
No respiratory 
symptoms + 
Candidiais, hypoparathyroidism, 
Addison’s disease, 
hypogonadism, intestinal 
dysfunction/malabsorbtion 
967-979del13/ 
967-979del13 
N.D. Denominates not done. N.A. denominates not applicable. Seven of eight patients with respiratory symptoms had antibodies to KCNRG, while 
KCNRG antibodies were positive in only one APS-1 patient without respiratory symptoms. 
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Table 1 
Please find the enclosed PDF-file for the Table.  
 
Figure legends 
 
Figure 1: Radiological and Histological Aspects of Pulmonary Involvement in APS-1 
Patients A) Pulmonary CT scan in patient 1 at the age of 11 years: peribronchial ground glass 
opacities B) Pulmonary CT scan in patient 1 at the age of 16 years, on immunosuppressive 
treatment with mycophenloate mofetil; the peribronchiolar abnormalities are improved. C 
and D) Histological appearance of lung biopsy in patient 1 at the age of 11 years (C, 10X 
magnification, D, 40X magnification): peribronchiolar lymphoid infiltrate. E) Pulmonary CT 
scan in patient 3 showing established bronchiectasis. F) Lung biopsy on patient 3 showing 
bronchiolitis obliterans organizing pneumonia. G and H) Histological appearance of lung 
biopsy in patient 4, at the age of 35 years, two years before his death from chronic respiratory 
failure (G, 10X magnification, H, 40X magnification); showing severe peribronchiolar 
infiltrate. 
 
Figure 2: Autoantibody Reactivity to KCNRG and Tissue Expression of KCNRG 
messenger RNA. A) Comparison of KCNRG autoantibody titers in sera from APS-1 patients, 
patients with different pulmonary disorders or other autoimmune disorders, and in sera of 
healthy blood donors. The assay for detection of autoantibodies is described in Methods. The 
dashed line indicates a cut of value of 0.41, which is the upper level of normal, defined as the 
mean results obtained for the healthy blood donors +3 SD. 
 
B) Expression of KCNRG mRNA in adult human tissues as measured by quantitative PCR, 
demonstrating that the expression of KCNRG is mainly restricted to pulmonary tissue. 
Please note the non-continuous y-axis. 
 
Figure 3. Distribution of KCNRG Protein in Bovine Lung. A-C). Immunohistochemistry 
on 4 µm paraffin embedded sections, using affinity-purified anti-KCNRG rabbit antiserum. 
A) Background staining without the primary antibody. B) Antiserum used in dilution 1:1000. 
C) Antiserum in dilution 1:1000 pre-absorbed with 20 nmol of the peptide used for the 
immunization. D-K) Immunofluorescence on 6 µm cryosections of lung, using patient and 
control serum samples. The blue background is from DAPI that stains nucleoli. FITC 
conjugated goat-anti-human IgG secondary antibody (green) was used. D) Background 
staining when no primary serum is used.  E-G) Staining with three APS-1 patients’ sera with 
KCNRG reactivity. H-I) Staining with two APS-1 sera without KCNRG reactivity. J-K) 
Staining with sera from two healthy blood donors. 
Figure 1
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Supplementary Appendix 
Methods 
Statistical Analysis 
Fisher’s exact test was used to determine the association of the KCNRG autoantibodies to 
different clinical manifestations of APS-1 in patients with the syndrome. 
DNA Sequencing and Analysis 
Isolated clones from immunoscreening of the cDNA library were subjected to in vivo excision 
of the pBK-CMV phagemid and automated BigDye Terminator cycle sequencing on an 
ABI377 sequencing machine (Applied Biosystems, Foster City, CA, USA). The human full 
length clones for 26kDa and 31kDa isoform of KCNRG IMAGE clones 4690662 and 
5207702 respectively were obtained from the UK HGMP Resource Centre (Cambridge, UK). 
DNA and deduced amino acid sequences were analyzed using the Basic Local Alignment 
Sequence Tool (BLAST) and Conserved Domain Database searches at www.ncbi.nih.gov. 
Amino acid sequences were also analyzed by use of the PSORT II program at 
psort.nibb.ac.jp. ClustalW alignments were performed at www.ebi.ac.uk. Computations of the 
theoretical molecular weights were performed by use of the Compute pI/Mw tool at 
us.expasy.org. 
Radioimmunoassay for KCNRG Autoantibodies and Immunoprecipitation Experiments 
The bovine KCNRG cDNA clone and the two human KCNRG full length splice variants were 
used as templates for coupled in vitro transcription/translation using the TnT system 
(Promega, Madison, WI, USA). For analysis of antibody reactivity against in vitro-translated 
KCNRG, a 96-well immunoprecipitation assay was used, essentially as described (References 
12-13 in the article). All sera were analyzed in duplicates. The immunoprecipitated 
radioactivity was evaluated in a liquid scintillation counter (Wallac 1450 MicroBeta). The 
screening serum (patient 6) and a healthy blood donor serum served as positive and negative 
controls, respectively. For each reaction, 20000 cpm of radiolabeled KCNRG and 2.5 µl of 
serum were used in a final volume of 50 µl. An anti-KCNRG reactivity index was calculated 
for each serum as follows: (cpm of unknown sample - cpm of negative control)/(cpm of 
positive control - cpm of negative control)*100. Upper level of normal was defined as the 
mean results obtained for the healthy blood donors included +3 SD and is indicated as a 
dashed line in the scattergram. The intra-assay and inter-assay coefficient of variations were 
10 % and 14 %, respectively. 
 
For the immunoprecipitation experiments in Supplementary Figure 3, immunoprecipitation 
was performed in microcentrifuge tubes. Typically, 20 000 cpm of the in vitro translation 
product was incubated with 2.5 μl serum in a final volume of 100 μl in 20 mM Tris-HCl pH 8, 
150 mM NaCl, 0.02% sodium azide and 1% Tween-20. After binding to Fast Flow Protein A 
Sepharose (GE-healthcare, Uppsala, Sweden) immune complexes were washed six times and 
bound proteins analyzed by SDS-PAGE followed by autoradiography using Phosphor 
Imager(Molecular Dynamics, Sunnyvale, CA, USA). 
 
Preabsorption Experiments  
To confirm the specificity of APS-1 patient sera for KCNRG, absorption studies were performed using 
serum samples from two patients (patients 6 and 7 described in Table 1) with KCNRG autoantibodies 
as detected in the autoantibody assay. Serum from these patients were diluted (1:800) in 
20 mM Tris-HCl pH 8, 150 mM NaCl, 0.02% sodium azide to a final volume of 800 μl and incubated 
over night with either 20 µl PBS (as a negative control), or 20 µl in vitro transcribed and translated 
and 35S-radiolabeled KCNRG (≈200 000 cpm), or 20 µl in vitro transcribed and translated and 
35S-radiolabeled Luciferase (≈1 000 000 cpm). After over night absorption, the preabsorbed serum 
samples were tested using immunofluorescence on bovine lung sections as described under methods in 
the manuscript. 
 
Immunohistochemistry on Tissue-Multi-Array (TMA) from the Swedish Human Protein 
Atlas Project 
A TMA slide as described on www.proteinatlas.org was stained with the KCNRG antiserum in 
dilution (1:2000) as described under Methods/Immunohistochemistry in the article. After the staining, 
counterstaining with hematoxylin and eosin was performed. 
 
Northern Blotting 
A 701 bp EcoRI fragment was excised from the KCNRG 31 kDa myc/his expression 
construct (see below) and used as template for synthesis of a 32P-labeled DNA probe by 
random priming with the Strip-EZ DNA kit (Ambion, Austin, TX, USA). The probe was 
purified by size exclusion chromatography on a NICK column (Amersham Biosciences, 
Uppsala, Sweden). A human 12-lane multiple tissue northern blot (BD Biosciences) was 
hybridized with the probe (~106 cpm/ml) in ULTRAhyb solution (Ambion). After washing, 
blots were analyzed by phosphorimaging. 
 
Quantitative Real-time PCR 
Real-time PCR was carried out on an iCycler MyiQ (Bio-Rad, Hercules, CA, USA) and 
analyzed using the software of the manufacturer. In a total volume of 25 µl, each reaction 
contained 2µl of the cDNA preparation provided in normalized multiple-tissue cDNA panels 
or normal human parathyroid cDNA, 300 nM of each primer pairs 
(KCNRG qPCRfw + KCNRG qPCRrev or GAPDHF + GAPDHR) and 12.5 µl 
iQ™ SYBR®-Green supermix (Bio-Rad). Cycling conditions were as follows: 95°C for three 
minutes, followed by 50 cycles of 55°C for 15 seconds and 60°C for 30 seconds. Melt curve 
analysis and direct sequencing of the PCR product verified the specificity of the amplification 
product.  The PCR analysis included a standard curve and non template negative controls. The 
relative amounts of the endogenous control glyseraldehyde-3-phosphate dehydrogenase 
(GAPDH) mRNA and the gene of interest mRNA in each sample could be deduced from the 
standard curves. 
 
Primer Sequences 
Primers were designed using the Beacon designer software (Premier Biosoft International, 
Paolo Alto) on the human genomic and cDNA sequence for 31kDa KCNRG. The following 
oligonucleotide primers (CyberGene AB, Huddinge, Sweden) were used for quantitative real 
time PCR: KCNRG qPCRfw, CAGGGAGGATTACAGTGTTTACAG; KCNRG qPCRrev, 
TTTATAGAAACATACCTGA CTCC ; GAPDHfw, AGGGCTGCTTTTAACTCTGGTAA: 
GAPDHrev,CATATTGGAAC ATGTAAACCATGTAGTT 
 
Hydrodynamic Parameters and Molecular Weight of KCNRG 
The sedimentation coefficient of in vitro-translated 35S-methionine-labeled bovine KCNRG 
cDNA was estimated by sucrose gradient sedimentation. Ten μl translation product was 
loaded on a gradient of 10-40% sucrose in PBS together with 100 μg bovine cytochrome c 
(sedimentation coefficient 1.86 S) and 0.5 μg rabbit IgG (6.7 S), which were used as internal 
standards along with the hemoglobin (4.4 S) present in the translation reaction. The tubes 
were centrifuged in a Beckman SW50.1 rotor at 50.000 rpm, at +4°C for 18 hours. Fractions 
were collected from the bottom of the tube and analyzed by scintillation counting, 
SDS-PAGE followed by phosphorimaging, spectrophotometry at 414 nm, to detect 
hemoglobin and cytochrome c, and direct ELISA to detect rabbit IgG. Radioactive bands in 
SDS-polyacrylamide gels were quantified using ImageQuaNT software (Molecular 
Dynamics).  
 
The Stokes radius (Rs) was estimated by size exclusion chromatography on a Superdex 
200 HR 30/10 column, connected to a BioLogic HR chromatography system with UV 
absorbance detection at 280 nm and a flow rate of 0.3 ml/min. The column was equilibrated 
with 20 mM Na-Hepes, containing 200 mM NaCl, pH 7.0 and 15 µl of the in vitro translation 
reaction was injected. The column was calibrated and the chromatograms analyzed as 
previously described (15), using the following standard proteins in two separate calibration 
runs applying four standards for each run: catalase (Rs 5.2 nm), transferrin (3.5 nm), 
ovalbumin (3.05 nm), myoglobin (2.11 nm), thyroglobulin (8.5 nm), apoferritin (6.1 nm), 
BSA (3.55 nm) and cytochrome C (1.7 nm). Blue dextran and acetone were used to determine 
the void volume (V0) and the total liquid volume inside the column (Vt), respectively. To 
detect the KCNRG translation product, fractions were analyzed by scintillation counting. 
 
Standard curves for sedimentation coefficients and Rs values were generated by linear 
regression analysis using Microsoft Excel 2002 software. The molecular weight of 
in vitro-translated bovine KCNRG was estimated from combined gel filtration and gradient 
sedimentation using the Svedberg equation: 
 
Mr = SN0(6πηRs)/(1-v2ρ) = 4,204S’Rs’ 
 
where Mr is molecular weight, S is the sedimentation coefficient, N0 is Avogadro's number, η 
is the viscosity of the solvent (0.01 poise), v2 is the partial specific volume of the protein 
(assumed to be 0.73 cm3/g) and ρ is the density of the solvent (1.0). For the numerical 
formulation on the right, S’ is in Svedberg units and Rs’ is in nm. 
 
Immunoprecipitation and Immunoblotting 
Bovine lung tissue was homogenized in 20 mM Tris-HCl pH 8, 150 mM NaCl, 0.02% sodium 
azide and 1% Triton X-100. After centrifugation, the supernatant was used for 
immunoblotting with the specific rabbit antiserum. As a control, non-radioactive in 
vitro-translated bovine KCNRG was used. 500 µl of the lysate was diluted 1:1 with Laemmli 
Sample Buffer (cat# 161-0737, Bio-Rad laboratories Hercules, CA) supplemented with 50 mM 
dithiothreitol and denatured at 95°C for 2 minutes and separated on a 12% Criterion SDS-PAGE 
Tris-HCl gel (cat#345-0019, Bio-Rad laboratories Hercules, CA) and transferred onto Nitrocellulose 
membrane (cat#162-0167 Bio-Rad laboratories Hercules, CA). Running and transfer conditions 
according to the manufacturer’s instructions (Bio-Rad). The blot was blocked with 5% dry milk for 30 
minutes and incubated with the primary antibody (1:400-1:2000) at 4°C overnight. After washing, 
bound primary antibodies were detected by a HRP conjugated secondary antibody using an ECL kit 
(Cat#RPN2132 GE Healthcare) according to the manufacturer’s instruction 
 
Results  
In Silico Analysis of KCNRG and Identification of KCNRG Orthologs 
BLAST searches of the nr database at NCBI revealed that the ortholog of this transcript is 
encoded on chromosome 13q14 in human and on chromosome 14 C3 in mouse. Unspliced 
transcripts of the 5’ end have been reported by Bullrich et al. who named the gene CLLD4 
(Bullrich, F. et al (2001) cancer Research 61, 6640-6648). By PCR amplification using 
specific primers, we were able to isolate two KCNRG splice variants from lung cDNA 
derived from both human and mouse (GenBank accession numbers AY190921-2 and 
AY491736-7). In human, these variants correspond to the human IMAGE clones 4690662 
and 5207702, of which the full sequences have been published by Ivanov et al. who used the 
gene name KCNRG (reference 18 in the article). In human, these splice variants are generated 
by alternative usage of a 98 bp middle exon that introduces a frame shift resulting in a smaller 
translation product. This exon is part of an Alu sequence of the Sp superfamily (GenBank 
accession number U14572, 90% nucleotide identity over 285 bp by BLASTN alignment). The 
two human splice variants encode proteins with predicted masses of 31 and 26 kDa, 
respectively. In mouse, two alternative splice sites exist at the 3’ end of exon 1, resulting in 
transcripts differing 34 bp in length, of which the longer variant contains a premature stop 
codon. By searching the EST database we also identified an ortholog transcript from Silurana 
tropicalis (IMAGE clone 5336560), of which we sequenced the entire open reading frame 
(GenBank accession number AY190924).  
 
The N-terminal region of KCNRG of all species contains a K_tetra or BTB/POZ domain 
motif (pfam02214 and smart00225, respectively), as identified by searches in the Conserved 
Domain Database. There is also a conserved leucine zipper motif in the 31 kDa isoform, as 
identified by the PSORT II program, located more to the C terminus. The frog sequence also 
contains two overlapping nuclear localization signal (NLS) motifs at positions 246-249 and 
247-250, respectively. 
 
Analysis of Autoreactivity Against Different Splice Variants of KCNRG 
To determine whether the autoantibodies against KCNRG distinguished between the 31 kDa 
and 26 kDa isoforms of the human protein, KCNRG positive APS-1 sera, KCNRG negative 
APS-1 sera and healthy blood donor sera were used in immunoprecipitation of 35S-labeled 
in vitro-translated bovine KCNRG, human 31 kDa isoform of KCNRG and human 26 kDa 
isoform of KCNRG proteins followed by analysis on SDS-PAGE and autoradiography. As 
shown in Supplementary Figure 3, sera from APS-1 patients with autoantibodies directed 
against KCNRG immunoprecipitated both the 26kDa and 31kDa human splice variants of 
KCNRG as well as bovine KCNRG, identically. This demonstrates that all these three 
isoforms of KCNRG contain the epitope recognized by patients’ autoantibodies. 
 
Expression Analysis of KCNRG mRNA by Northern Blot. 
Tissue distribution of KCNRG was investigated by northern blotting. A multiple tissue 
northern blot was hybridized with a cDNA probe corresponding to amino acids 42-273 of the 
31 kDa isoforms, thus lacking part of the K_tetra/BTB/POZ domain sequence, to reduce 
possible cross-hybridization (Supplementary Figure 1). In the lung lane, a specific band at 
~1.35 kb is seen. In most of the lanes, there is a band at ~7.5 kb, presumably due to 
cross-hybridization with transcripts of the overlapping or existence of additional splice 
variants.  
 
Illustration of KCRNG’s Appearance as Monomers and Tetramers in vitro 
As the N terminus of KCNRG contains a K_tetra/BTB/POZ domain motif, which is known to mediate 
oligomerization in other proteins such as ion channels, we investigated the hydrodynamic 
characteristics of in vitro-translated KCNRG. Bovine KCNRG (which gave the best yields of 
translation product) was subjected to ultracentrifugation on a sucrose gradient and size exclusion 
chromatography, and fractions were analyzed. As shown in Supplementary Figure 2A, the in vitro-
translated protein was found to give rise to two distinct sedimentation peaks with apparent 
sedimentation coefficients of approximately 2.7 S and 6.4 S, respectively. A similar profile was 
obtained in the absence of cytochrome c and IgG, indicating that these proteins do not interfere (not 
shown). Size exclusion chromatography also resulted in two separate peaks corresponding to 
estimated Rs values of 3.1 and 5.4 nm, respectively (Supplementary Figure 2B). From these 
sedimentation coefficients and Rs values, the molecular weight of the two forms of KCNRG could be 
estimated to 36 and 146 kDa, respectively. Given the predicted molecular weight of the polypeptide 
monomer (30 kDa), these values indicate that KCNRG exist as tetramers and monomers in vitro, 
although complex formation with other proteins in the translation reaction cannot be excluded by these 
experiments. 
. 
APS-1 Disease Component 
Number of 
Patients with  
Number with antibodies to 
KCNRG/total  P value 
  
Disease 
component/total 
 
  
   (Percent) With disorder Without disorder   
Self-reported pulmonary 
symptoms     8/110 (7%) 7/8     (88 %) 1/102 (1%)   <0.0001 
Candidiasis 105/110 (95%) 8/105 (8%) 0/5     (0%) 0.45 
Hypoparathyroidism 93/110   (85%) 7/93    (8%) 1/17   (6%)  0.54 
Addison's disease 87/110   (79%) 7/87    (8%) 1/23   (4%) 0.31 
Hypogonadism 32/110   (29%) 3/32    (9%) 5/78   (6%) 0.78 
Alopecia 38/110   (35%) 3/38    (8%) 5/72   (7%) 0.51 
Vitiligo 22/110   (20%) 1/22    (5%) 7/88   (8%) 0.35 
Hepatitis* 22/110   (20%) 5/22    (23%) 3/88   (3%) 0,002* 
Insulin-dependent  12/110   (11%) 0/12    (0%) 8/98   (8%) 0,22 
Diabetes mellitus     
 
Supplementary Table 1 
Association between clinical manifestations of APS-1 and the presence of KNRG autoantibodies. 
Fisher’s two-tailed exact test was used to compare the data between the two groups of patients with 
autoantibodies directed against KCNRG, and the P values reported. A statistically significant 
correlation was found for pulmonary symptoms. Nevertheless, since the diagnosis of pulmonary 
symptoms is based on patient self-report, the entire cohort has not been subject to lung function test. 
Hence, the possible existence of unreported cases within the cohort should be taken in consideration 
when interpreting the statistical data. * It is notable that the presence of KCNRG autoantibodies 
appears to show a statistically significant correlation to hepatitis. The expression of KCNRG in 
hepatocellular carcinoma has previously been reported (Cho YG et al. Exp Mol Med. 2006;38(3):247-
55). These findings could be in parallel, nevertheless, the sensitivity of the test appears to be higher for 
respiratory symptoms than hepatitis. Moreover, other well established and clinically reliable 
autoantigens for APS-1 associated hepatitis (Cytochrome P4501A2 and aromatic L-amino acid 
decarboxylase) are previously described and the autoantibodies directed against these autoantigens 
appear to have higher sensitivity and specificity for hepatitis, and hence, better markers than KCNRG 
for diagnosis of hepatitis. 
 
Legends to Supplementary Figures 
Supplementary Figure 1 
Expression Analysis of KCNRG mRNA by Northern Blot. 
Human multiple tissue Northern blot hybridized with 32P-labeled KCNRG cDNA probe. 
Positions of molecular weight markers are shown on the left. The position of the ~1.35 kb 
band in the lung lane is indicated by the arrow. 
 
Supplementary Figure 2 
Sedimentation Analysis of 35S-labeled in vitro-Translated Bovine KCNRG by 
Ultracentrifugation on a 10-40 % Sucrose Gradient. The 35S-radiolabeled KCNRG was 
detected in collected fractions by autoradiography after separation by SDS-PAGE. The band 
volumes detected by Phosphor Imager and analyzed by the ImageQuaNT software (Molecular 
Dynamics), are plotted in the line graph. Positions of sedimentation standards are indicated by 
the vertical arrows. B). Size exclusion chromatography of 35S-labeled bovine KCNRG 
synthesized by in vitro transcription and translation. Fractions were collected and the 
translation product was detected by scintillation counting. V0, Void volume; Vt, total volume. 
 
Supplementary Figure 3  
Immunoprecipitation of 35S-Radiolabelled KCNRG Isoforms with APS-1 Patient Sera. 
Radiolabeled bovine KCNRG, and the 26kDa and 31kDa splice variants of human KCNRG, 
with sera from APS-1 patients with KCNRG autoantibodies (first three lanes from left), sera 
from APS-1 patients without KCNRG autoantibodies (lanes 4-6 from left), and sera from 
healthy blood donors (NHS) (lanes 7-8 from left). The immunoprecipitates were size 
determined by SDS-PAGE followed by autoradiography. These results indicate that the three 
different isoforms of KCNRG are recognized identically by sera from APS-1 patients. 
 
Supplementary Figure 4  
Immunoblot Experiment to Verify the Specificity of the KCNRG Antiserum 
To test the specificity of the KCNRG antiserum, in vitro-translated bovine KCNRG (lane 1) 
and bovine lung tissue protein lysate (lanes 2-4) were separated by SDS-PAGE and 
transferred to a membrane. The membrane was blotted with the KCNRG antiserum in dilution 
1:5000 for lane 1-2 and 1: 10000 for lane 3. In lane 4, the antiserum in dilution 1:10 000 was 
first preincubated overnight with 100 nmol of the peptide used for immunization of the 
rabbits. The antiserum recognizes in vitro-translated bovine KCNRG as well as KCNRG in 
the lung protein lysate. 
 
Supplementary Figure 5  
Preabsorption Studies to Confirm the Specificity of Autoantibodies for KCNRG in 
Patients with APS-1. Immunofluorescence was performed on cryosections of bovine lung 
with the use of serum from two different APS-1 patients (patients 6 and 7 from Table 1). 
Panels A-C correspond to patient 6 and panels D-F correspond to patient 7. The serum 
samples were diluted (1:800) and preincubated with either no protein (panels A and D), or an 
equal amount of in vitro transcribed and translated KCNRG labeled with 35S-methionine 
(panels B and E) or luciferase (Panels C and F). The results demonstrate that patient 
autoantibodies can be blocked by KCNRG and not by an irrelevant protein, suggesting that 
the autoantibodies directed to the terminal bronchioles are specific for KCNRG.  Scale bars 
represent 100μm. 
 
Supplementary Figure 6  
Tissue Distribution of the KCNRG Protein. To exclude ubiquitous expression of KCNRG, 
the KCNRG antiserum was used in dilution 1:2000 to stain a human multi-tissue array 
previously described in the Swedish Human Protein Atlas Project (www.proteinatlas.org). 
The antiserum showed strong but unattractive staining of the tissue spot designated bronchus. 
Moreover weak staining could bee seen in prostate and pancreas. Taken together, the tissue 
protein expression of KCNRG appears to be in line with the mRNA expression data presented 
in Figure 2B of the manuscript.  
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